Expanding Applications for Intravenous Platelet Inhibition
The decision to use P2Y12 Inhibitors has been the cornerstone treatment of patients with acute coronary syndrome (ACS). Through case presentations, find out about optimal anti-platelet coverage in patients with ACS and complex stable CAD and the pharmacotherapy treatments. Gain valuable insight into the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Plus, learn vital tips from experts in the field to help you with the transition to oral P2Y12 receptor blockades.